论文部分内容阅读
目的:血清CEA,CA125已被广泛应用于临床多种肿瘤的诊断和预后检测中。本文旨意在探讨检测胸水CEA,CA125在良恶性胸腔积液鉴别诊断中的临床价值。方法:同时收集64例肺癌患者的血清及胸腔积液的标本,其中腺癌29例,鳞癌24例,小细胞未分化癌11例;肺部良性病变62例作对照组。采用ABBOTT公司提供的AXSYM型全自动免疫分析仪进行检测。结果:肺癌组血清和胸水CEA,CA125的测定值高于对照组(P<0.01),有显著性差异;肺癌组胸水CEA,CA125水平明显高于血清水平(P<0.01),差异有显著性;肺癌组胸水CEA,CA125阳性率分别为67.2%,57.8%,与对照组阳性率(分别为11.3%,9.7%)比较差别均有统计学意义(P<0.01)。结论:胸水中CEA,CA125检测有利于良恶性胸腔积液的鉴别诊断,且胸水中CEA,CA125比血清中更具有临床价值。
Objective: Serum CEA, CA125 has been widely used in clinical diagnosis and prognosis of a variety of tumors. This article aims to explore the clinical value of detecting pleural effusion CEA, CA125 in the differential diagnosis of benign and malignant pleural effusion. Methods: Serum and pleural effusion were collected from 64 patients with lung cancer, including 29 cases of adenocarcinoma, 24 cases of squamous cell carcinoma, 11 cases of small cell undifferentiated carcinoma and 62 cases of benign lung disease. Using ABBOTT company AXSYM automatic immune analyzer for testing. Results: The levels of CEA and CA125 in serum and pleural effusion in lung cancer group were significantly higher than those in control group (P <0.01), and the levels of CEA and CA125 in pleural effusion in lung cancer group were significantly higher than those in serum (P <0.01), the difference was significant . The positive rates of CEA and CA125 in pleural effusion were 67.2% and 57.8% in lung cancer group respectively, which were significantly different from those in control group (11.3% and 9.7%, respectively) (P <0.01). Conclusion: The detection of CEA and CA125 in pleural fluid is good for the differential diagnosis of benign and malignant pleural effusions, and CEA and CA125 in pleural fluid are more valuable than serum.